Building specialty psilocybin-based product pipeline Evaluating potential for neuropsychiatric indications for clinical studies in 2022 TORONTO, Nov. 03, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare…
